× Digital News Videos Health & Science Opinion Education Columnists Cartoons Lifestyle Moi Cabinets Arts & Culture Ramadhan Special Podcasts E-Paper Lifestyle & Entertainment Nairobian Entertainment Eve Woman Travelog TV Stations KTN Home KTN News BTV KTN Farmers TV Radio Stations Radio Maisha Spice FM Vybez Radio Enterprise VAS E-Learning Digger Classified Jobs Games Crosswords Sudoku The Standard Group Corporate Contact Us Rate Card Vacancies DCX O.M Portal Corporate Email RMS

Potential new malaria vaccine shows promise in Burkina Faso trial

By Mirror | April 24th 2021
A doctor tests a child for malaria at the Ithani-Asheri Hospital in Arusha, Tanzania, file. [Reuters]

A potential new malaria vaccine has proved highly effective in a trial in babies in Africa, pointing to it one day possibly helping reduce the death toll from the mosquito-borne disease that kills up to half a million young children a year.

The candidate vaccine, developed by scientists at Britain’s University of Oxford and called R21/Matrix-M, showed up to 77% efficacy in the year-long trial of 450 children in Burkina Faso, researchers leading the trial said in a statement.

The scientists, led by Adrian Hill, director of Oxford’s Jenner Institute and also one of the lead researchers behind the Oxford-AstraZeneca COVID-19 vaccine, said they now plan to conduct final stage trials in some 4,800 children aged between 5 months and 3 years in four African Countries.

Hill said he had “high expectations for the potential of this vaccine” which he said would be the first against malaria to reach a World Health Organization (WHO) goal of a malaria shot with at least 75% efficacy.

Scientists around the world have been working for decades to develop a vaccine to prevent malaria - a complex infection caused by a parasite carried in the saliva of mosquitoes.

Malaria infects millions of people every year and kills more than 400,000 - most of them babies and young children in the poorest parts of Africa.

The world’s first and only licensed malaria vaccine, Mosquirix, was developed by GlaxoSmithKline over many years of clinical trial across several African countries, but is only partially effective at around 30%.

In the R21/Matrix-M trial in Burkina Faso, the 450 young children were divided into three groups. Two groups got three doses of the experimental vaccine along with either a low or a high dose of an adjuvant - an ingredient designed to super-charge the body’s response to a vaccine - while the third group was given a control vaccine.

Take a quick survey and help us improve our website!

Take a survey

Results, which researchers said would soon be published in The Lancet medical journal, showed efficacy of 77% in the high-dose adjuvant group and 74% among those who got the vaccine with a low-dose of adjuvant.   

Covid 19 Time Series


Share this story
Covid-19: Kenyan Embassy in India reaches out to affected citizens
India recorded 346,786 fresh cases, setting a new world record for the third consecutive day
Former rugby player Alex Olaba detained for seven days in attempted murder case
A court has directed former rugby player Alex Olaba be remanded for seven days at Kilimani Police Station to allow detectives to complete investigatio